

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

Director/PDMR Dealing

Cambridge, UK, 21 May 2025. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that Andrew Richards (Chair), Sarah Howell (Chief Executive Officer) and Jan Jezek (Chief Scientific Officer) have all purchased ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares"). Details are included in the table below.

Name	Number of Ordinary Shares purchased	Price (£)	Total beneficial interest (Ordinary Shares)	Total beneficial interest (%)
Andrew Richards	31,750	0.4697	318,361	0.84%
Sarah Howell	21,077	0.4697	905,481	2.40%
Jan Jezek	10,000	0.4700	417,808	1.11%

-ENDS-

For more information, please contact:

Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

David Ellam, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Singer Capital Markets Advisory LLP (NOMAD and Broker)

Phil Davies, Sam Butcher

Tel: +44 (0) 20 7496 3000

ICR Healthcare

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@icrhealthcare.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Andrew Richards
2	Reason for the notification	
a)	Position/status	Chair
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Arecor Therapeutics plc

b)	LEI	98450093D1213A8DDD58
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares
b)	Identification Code	GB00BMWLM973
c)	Nature of the transaction	Purchase of Ordinary Shares
d)	Price(s) and volume(s)	£0.4697 and 31,750 Ordinary Shares
e)	Aggregated information - Aggregated volume - Aggregated price	N/A
f)	Date of the transaction	19 May 2025
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Sarah Howell
2	Reason for the notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Arecor Therapeutics plc
b)	LEI	98450093D1213A8DDD58
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares
b)	Identification Code	GB00BMWLM973
c)	Nature of the transaction	Purchase of Ordinary Shares
d)	Price(s) and volume(s)	£0.4697 and 21,077 Ordinary Shares
e)	Aggregated information - Aggregated volume - Aggregated price	N/A
f)	Date of the transaction	19 May 2025
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Jan Jezek
2	Reason for the notification	
a)	Position/status	Chief Scientific Officer

b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Arecor Therapeutics plc
b)	LEI	98450093D1213A8DDD58
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares
b)	Identification Code	GB00BMWLM973
c)	Nature of the transaction	Purchase of Ordinary Shares
d)	Price(s) and volume(s)	£0.4700 and 10,000 Ordinary Shares
e)	Aggregated information - Aggregated volume - Aggregated price	N/A
f)	Date of the transaction	20 May 2025
g)	Place of the transaction	London Stock Exchange, AIM

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHAMMRTMTBTBJA